NorthWest Biotherapeutics Inc (NWBO)

[jondoeuk]

Another TLR9 agonist could. In the next few months a PhIII testing intratumoral IMO-2125 (produced by $IDRA) in PD-1 R/R patients will open. They hope to recruit approximately 300 patients at ~70 centers globally.

Two other trials are ongoing in patients with a range of solid tumours (NCT03052205) and metastatic melanoma in combo with either Ipilimumab or Pembrolizumab (NCT02644967).

In the former trial all subjects dosed (N=11) completed the 21 day DLT
period. No DLTs or safety concerns have occurred. Cohort 1 (8 mg) diseases under study included pancreatic cancer (6), ocular melanoma (1), colorectal cancer (1), metastatic chondrosarcoma (1), metastatic breast cancer (1), metastatic esophageal cancer (1). Eight subjects had injections into their liver lesions and now Cohort 2 (16 mg) is enrolling. Three subjects in cohort 1 (8 mg) continue IMO-2125 monotherapy. Initial investigator assessments indicate stable disease in 2 patients (pancreatic, colorectal), and another 1 has irSD (pancreatic).